Overview

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

To compare the pharmacokinetics and safety after a single dose administration of Telmione plus® 80/12.5mg and Micardis plus® 80/12.5mg in healthy adult volunteers

Phase:

Phase 1

Details

Lead Sponsor:

HK inno.N Corporation

Treatments:

Telmisartan